How India Exports Lansoprazole to the World

In the United States, lansoprazole is approved under multiple Abbreviated New Drug Applications (ANDAs), indicating a well-established generic market. Notably, Wockhardt Limited received approval for lansoprazole delayed-release capsules USP, 15 mg (OTC) on May 14, 2012. The FDA's Orange Book lists numerous approved ANDAs for lansoprazole, reflecting its widespread acceptance. The absence of current import alerts for lansoprazole suggests compliance with FDA standards. Given that 316 Indian exporters are active in this market, adherence to FDA regulations is crucial for maintaining market access.

In the European Union, lansoprazole has undergone various regulatory evaluations. For instance, the European Medicines Agency (EMA) conducted a referral procedure for Agopton (lansoprazole) in September 2006 to harmonize product information across member states. (ema.europa.eu) Additionally, the EMA has assessed periodic safety update reports for lansoprazole, with the most recent evaluation in October 2022. (ema.europa.eu) In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a Class 4 Medicines Notification in February 2025 regarding a minor labeling error for lansoprazole gastro-resistant hard capsules 15 mg. (gov.uk) Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for market authorization in these regions.

Lansoprazole is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. It meets international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across markets.

In India, lansoprazole is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, specific pricing details for lansoprazole should be verified with the latest NPPA notifications. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for compliance with export regulations.

The primary patents for lansoprazole have expired, leading to a competitive generic market. This expiration has facilitated the entry of multiple manufacturers, including Indian exporters, into global markets.

In October 2022, the EMA concluded a periodic safety update report for lansoprazole, resulting in variations to the terms of marketing authorizations. (ema.europa.eu) In February 2025, the UK's MHRA issued a Class 4 Medicines Notification due to a labeling error on lansoprazole capsules, highlighting the importance of accurate product information. (gov.uk) These developments emphasize the need for continuous regulatory compliance and vigilance in the pharmaceutical industry.

India's pharmaceutical industry, including the production of Lansoprazole, has historically relied heavily on China for Key Starting Materials (KSMs) and certain Active Pharmaceutical Ingredients (APIs). This dependency has exposed the supply chain to vulnerabilities, particularly when Chinese manufacturers faced shutdowns due to environmental regulations and compliance issues. For instance, in 2018, several Chinese API producers were closed for failing to adhere to pollution norms, leading to supply disruptions and increased costs for Indian pharmaceutical companies.

In response to these challenges, the Indian government introduced the Production Linked Incentive (PLI) scheme to bolster domestic API manufacturing and reduce reliance on imports. This initiative aims to enhance local production capabilities, promote technological advancements, and ensure a more resilient supply chain for critical drugs like Lansoprazole. (pharmanow.live)

Our proprietary trade data indicates a significant concentration in Lansoprazole exports from India, with the top five exporters accounting for 79.8% of the total export value. Notably, SANDOZ PRIVATE LIMITED alone contributes 54.8% of this share. Such concentration poses a single-source risk, where disruptions affecting these key suppliers could have a disproportionate impact on global supply.

The PLI scheme, initiated by the Indian government, is designed to mitigate these risks by incentivizing a broader base of manufacturers to produce APIs domestically. By diversifying the supplier base and enhancing production capacity, the scheme aims to reduce the industry's vulnerability to supply disruptions and ensure a more stable supply of essential medications. (pharmanow.live)

Recent geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz following military conflicts led to substantial disruptions in the transportation of goods, including pharmaceuticals. This chokepoint is vital for global commerce, and its obstruction has caused delays and increased costs for shipments originating from India.

Additionally, instability in the Red Sea and the Suez Canal, exacerbated by regional conflicts, has forced shipping companies to reroute vessels around the Cape of Good Hope. This detour adds approximately 10 to 14 days to transit times, further straining supply chains and escalating transportation costs.

The U.S. Food and Drug Administration (FDA) has acknowledged these challenges, emphasizing the need for proactive measures to monitor and mitigate potential drug shortages resulting from such geopolitical disruptions.

• Diversify Supplier Base: Encourage the development of multiple domestic API manufacturers to reduce reliance on a limited number of suppliers and enhance supply chain resilience.

• Strengthen Domestic Production: Leverage government initiatives like the PLI scheme to boost local API production capabilities, thereby decreasing dependency on imports and mitigating risks associated with international supply disruptions.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to gain real-time insights into supply chain operations, enabling prompt responses to potential disruptions.

• Develop Contingency Plans: Establish comprehensive risk management strategies, including alternative shipping routes and logistics partners, to ensure continuity in the face of geopolitical tensions and transportation challenges.

• Engage in International Collaboration: Work closely with global regulatory bodies and industry stakeholders to share information, coordinate responses to supply chain disruptions, and develop standardized protocols for crisis management.

RISK_LEVEL: MEDIUM